Heron Therapeutics Q3 EPS $(0.03), Inline, Sales $35.250M Miss $37.500M Estimate

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $35.250 million which missed the analyst consensus estimate of $37.500 million by 6.00 percent. This is a 7.75 percent decrease over sales of $38.213 million the same period last year.